Jesse Shustik

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 366 citations

Hematological Malignancy, Relapsed Multiple Myeloma, Medicine +11

Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy

Jesse Shustik, Melanie Quinn, Joseph M. Connors et al. · Annals of Oncology · 2010 · 74 citations

Hematological Malignancy, Anthracycline-based Therapy, Lymphoid Neoplasia +10

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP

Jesse Shustik, Gencheng Han, Pedro Farinha et al. · Haematologica · 2009 · 70 citations · Full text

Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Laurie H. Sehn, Edward Hardy, Karamjit Gill et al. · Blood · 2014 · 32 citations

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michaël Sébag, Nizar J. Bahlis, Christopher P. Venner et al. · Blood · 2019 · 12 citations